Mubadala and G42 group have partnered to start a biopharmaceutical manufacturing plant in Abu Dhabi.
The facility will invest in and establish multiple initiatives, leveraging the expertise of Mubadala’s advanced manufacturing companies as well as G42’s capabilities in artificial intelligence and cloud computing.
The agreement promotes advances in the UAE’s socio-economic growth and diversification while also improving health outcomes across the nation and the wider Middle East region.
Global supply shortages have resulted in biopharmaceuticals becoming a high growth market with a 10 per cent compound annual growth rate (CAGR) over the past five years and have become a priority investment area for Mubadala within the life sciences sector.
The ability of biopharmaceutical products to address previously untreatable conditions has also inspired confidence in the market’s long-term and future growth potential.
China's Xi pushes for global AI body at APEC in counter to US
ADNOC Distribution reports $579 million net profit in first 9 months
TECOM Group’s 9-month shows 20% revenue growth
DFM reports 212% increase in net profit before tax to AED930.8 million
DMCC unveils plans for new financial centre
